UF News

Yikes! Scientists Discover Factor That Directs Brain’s Fear Conditioning

A team led by neuroscientists at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology has discovered a key molecular player in fear conditioning. It’s a specialized RNA with a memorable acronym, SLAMR. Their study found SLAMR must be present in adequate quantities for neurons to build the complex connections required for fear conditioning. Their research appears in the journal Nature Communications.

Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands Product Series to Breath Logix

UF startup Cannabix Technologies Inc., developer of marijuana and alcohol breath-testing devices reports that it has shipped its Industrial Series Contactless Alcohol Breathalyzers (“CAB” devices) for certification testing and is rebranding the “CAB” name under the new “Breath Logix” product series, part of the company’s portfolio of marijuana and alcohol screening devices.

Researchers Create a New AI Pipeline for Identifying Molecular Interactions

Understanding how proteins interact with each other is crucial for developing new treatments and understanding diseases. Thanks to computational advances, a team of researchers led by Assistant Professor of Chemistry Alberto Perez have developed a groundbreaking algorithm to identify these molecular interactions.

Fang Invited to Present at the National Academies’ Workshop on Bidirectionality Between AI & Neuroscience

UF researcher Dr. Ruogu Fang was invited to present at The National Academies’ Workshop on Bidirectionality between AI and Neuroscience. The invitation comes from The National Academies Forum on Neuroscience and Nervous System Disorders, organizing a hybrid workshop titled “Exploring the Bidirectional Relationship between Artificial Intelligence and Neuroscience.” The workshop occurred on March 25-26 in Washington, D.C.

Ascend Acquires Beacon Gene Therapy Manufacturing Site

Ascend Advanced Therapies, a gene therapy development partner, has purchased Beacon Therapeutics’ contract, manufacturing, and controls team—along with the company's site, previously owned by UF Innovate | Accelerate graduate AGTC, located in Alachua, FL—a town considered to be a “biotech hub” in the state. The acquisition introduces a good manufacturing practice (GMP) plant into the fold, along with process and analytical development capabilities.

Want our news in your inbox every Monday morning? You can!

Subscribe Here